Back to Screener

Healthcare

Viva Biotech Holdings(VBIZF)

Live Price

Offline

$0.1349

+0.00% today

1Y Change

-32.60%

Window

Jun 23, 2025 โ†’ Jun 15, 2026

Market Cap
$3.11B
Revenue Growth
-15.2%
EPS Growth
+27.7%
Dividend Yield
0.0%

Coverage: 253 bars ยท Jun 23, 2025 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Viva Biotech Holdings (VBIZF) is a Healthcare stock with a market cap of $3.11B and listed on OTC. The stock last traded around $0.13 and down 32.6% across the available one-year price window (Jun 23, 2025 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of -15.2%, EPS growth of +27.7%, a dividend yield of 0.0%. What stands out right now is revenue -15.2%, EPS +27.7%, free cash flow -51.7% with operating margin 11.2% and ROIC 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 6.4 and price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VBIZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

-15.2% vs +7.6% peer median

Operating Margin

Below sector median

+11.2% vs +19.4% peer median

P/E

Below sector median

6.4 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating picture looks softer than before

Revenue is at -15.2% and EPS is at +27.7%, with operating margin around 11.2%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

VBIZF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

VBIZF Max Drawdown

-65.07%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for VBIZF and SPY.

Calendar-year return history is still loading or unavailable.
Viva Biotech Holdings logo

Company Overview

Viva Biotech Holdings

Other OTC

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.

Leadership
Chen Cheney Mao
IPO Date
Sep 25, 2019
Employees
2.1k
Street Address
No.735, Ziping Road
Mailing
Shanghai, 201318
Region
Shanghai, CN
Reporting Currency
USD
Investor Line
86 21 6089 3288
Last Updated
May 5, 2026
ISIN: KYG9390W1015
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
6.4
EV/EBITDA
8.5
Price/Sales
1.8
Price/Book
0.4

Growth

Revenue
-15.2%
EPS
+27.7%
Free Cash Flow
-51.7%

Profitability

Gross Margin
37.9%
Operating Margin
11.2%
Net Margin
12.7%
ROE
5.5%
ROIC
2.4%

Balance Sheet

Debt/Equity
0.33
Current Ratio
1.50

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.